The first line of therapy for many inflammatory diseases as well as respiratory infections is Dex, which lowers the expression of pro-inflammatory cytokines including IL-6, and which has been proven effective in COVID-19 patients requiring, invasive or not, oxygenation [34,35]. The gene discussed is IL6; the disease is respiratory tract infectious disorder.